Tocilizumab

Tocilizumab treatment in early interstitial lung disease, with progressive skin involvement related to systemic sclerosis, was able to stabilize forced vital capacity over 48 weeks, according to data published in Arthritis & Rheumatology.

Inhibition of the interleukin-6 mediated immune response with tolicizumab (Actemra, Genentech) vs. placebo in out-of-hospital cardiac arrest.

Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in patients with systemic juvenile idiopathic arthritis, according to findings published in Rheumatology.

Compared with usual care, tocilizumab reduced deaths by an absolute difference of 4% among patients with COVID-19 who required oxygen and had evidence of inflammation, investigators from the RECOVERY trial reported Thursday.

Tocilizumab, an interleukin-6 inhibitor, successfully reduced systemic inflammation and cardiac injury in resuscitated comatose patients with out-of-hospital cardiac arrest compared with placebo, according to results of the IMICA trial.

Tocilizumab may lower the odds of needing mechanical ventilation among patients hospitalized with COVID-19 pneumonia, but not the risk for death, according to research published in the New England Journal of Medicine.

The addition of tocilizumab to the standard of care fails to prevent mechanical ventilation or death in patients moderately ill with COVID-19, according to a speaker at ACR Convergence 2020.

Three studies recently published in JAMA Internal Medicine evaluated the effects of tocilizumab against COVID-19.

Patients with polyarticular-course juvenile idiopathic arthritis achieved high-level disease control for up to 2 years when treated with tocilizumab, according to data published in Arthritis & Rheumatology.

Myocardial salvage in patients with first-time acute STEMI treated with tocilizumab (Actemra, Genentech) or placebo.